The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J, Alerany-Pardo C, Borrás-Blasco J, Broto-Sumalla A, Burgos-SanJosé A, Climent-Bolta C, Escudero-Vilaplana V, Fernández-Fuente MA, Ferrit-Martin M, Gómez-Germá P, Martínez-Sesmero JM, Mayorga-Pérez J, Menchén-Viso B, Merino-Alonso J, Polache-Vengud J, Sánchez-Guerrero A.
Martinez-Cutillas J, et al.
Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):851-8. doi: 10.1586/14737167.2015.1044514. Epub 2015 May 14.
Expert Rev Pharmacoecon Outcomes Res. 2015.
PMID: 25972066